“骗保”案的道德困境治疗癌症的代价与医保的规范最近闹得沸沸扬扬的“骗保”案，最终很多涉案人员都被判处不同程度的刑罚。然而，很多人在谴责医保局和医保政策，今天从个人角度简单说说这件事的想法。涉案的药物叫做Osimertinib ...

Get detailed information on Garenoxacin Mesylate, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated ...

Transformative Financing worth up to $275 million from Top-Tier Institutional Healthcare Investors ---- Advancement of IkT-001Pro into a ...

Eribulin exerts its pharmacologic effects by binding to the plus ends of microtubules and suppressing microtubule growth, without affecting microtubule shortening, and by inducing the formation of ...

回顾2024ASCO大会HER2阳性晚期乳腺癌治疗领域最新研究进展。 2024年美国临床肿瘤学会（ASCO）年会于5月31日-6月4日在芝加哥盛大召开，作为全球最有 ...

The FDA approved zolbetuximab (Vyloy) on October 18, 2024, as a first-line treatment for locally advanced unresectable or ...

There are also oral medications in phase III based on a possible action against tau, such as simufilam and ...

For chronic myeloid leukemia (CML) patients, there is a promising new first-line drug approval with asciminib (brand name ...

Boyle's research team also found that the 2GF-mediated increase in proinflammatory cytokine levels in fibroblast-like synoviocytes could be inhibited by treatment with imatinib mesylate—a ...

a MAO-B = monoamine oxidase type B, MAO-A = monoamine oxidase type A. b Expressed as the molar concentration of drug required to inhibit enzyme activity by 50% (nmol/L). c Expressed as the ...

Over the last 2 decades, significant progress has been made in our understanding of the genomics, tumor immune microenvironment, and immunogenicity of malignant melanoma. Historically, the prognosis ...